Cargando…
TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
In ovarian cancer patients a 6 kDa polypeptide, the tumour-associated trypsin inhibitor (TATI), can occur at elevated concentrations in both urine and serum. In this study pretreatment serum levels of TATI (cut-off point 21 ng ml-1) and CA 125 (cut-off points 35 U ml-1 and 65 U ml-1) were determined...
Autores principales: | Medl, M., Ogris, E., Peters-Engl, C., Leodolter, S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033783/ https://www.ncbi.nlm.nih.gov/pubmed/7734298 |
Ejemplares similares
-
Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
por: Halila, H., et al.
Publicado: (1988) -
Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990) -
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
por: Halila, H., et al.
Publicado: (1987) -
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.
por: Haglund, C., et al.
Publicado: (1986) -
Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
por: Venesmaa, P., et al.
Publicado: (1994)